Ultra-high-risk pediatric cancer - combinatorial drivers and therapeutic targets for precision medicine
Dauer: 60 Monate, Fördersumme: € 799.350
PHARMACOSCOPY: Breaking resistance of refractory blood cancers through ex vivo automated image-based analysis of drug action
Dauer: 46 Monate, Fördersumme: € 904.000